Free Trial
NASDAQ:IMMX

Immix Biopharma (IMMX) Stock Price, News & Analysis

Immix Biopharma logo
$2.39 0.00 (0.00%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Immix Biopharma Stock (NASDAQ:IMMX)

Key Stats

Today's Range
$2.36
$2.47
50-Day Range
$2.06
$2.99
52-Week Range
$1.26
$3.20
Volume
16,384 shs
Average Volume
162,798 shs
Market Capitalization
$66.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Immix Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

IMMX MarketRank™: 

Immix Biopharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 489th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immix Biopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Immix Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Immix Biopharma are expected to grow in the coming year, from ($0.87) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immix Biopharma is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immix Biopharma is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immix Biopharma has a P/B Ratio of 4.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immix Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    1.38% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immix Biopharma has recently increased by 37.70%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immix Biopharma does not currently pay a dividend.

  • Dividend Growth

    Immix Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.38% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immix Biopharma has recently increased by 37.70%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Immix Biopharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,061.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    55.40% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.26% of the stock of Immix Biopharma is held by institutions.

  • Read more about Immix Biopharma's insider trading history.
Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

IMMX Stock News Headlines

Immix Biopharma Announces Other Serious Diseases Strategy
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
Immix Biopharma Attends FDA CEO Forum in Washington DC
See More Headlines

IMMX Stock Analysis - Frequently Asked Questions

Immix Biopharma's stock was trading at $2.20 on January 1st, 2025. Since then, IMMX stock has increased by 8.6% and is now trading at $2.39.

Immix Biopharma, Inc. (NASDAQ:IMMX) announced its quarterly earnings data on Monday, March, 24th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09.

Immix Biopharma (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share.

Immix Biopharma's top institutional investors include Tritonpoint Wealth LLC (0.09%). Insiders that own company stock include Ilya M Rachman, Jason Hsu, Gabriel S Morris, Carey Ng, Helen C Adams and Magda Marquet.
View institutional ownership trends
.

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

Last Earnings
3/24/2025
Today
8/08/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMMX
CIK
1873835
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$7.00
Potential Upside/Downside
+192.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.61 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-130.02%
Return on Assets
-86.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.80
Quick Ratio
1.80

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
4.98

Miscellaneous

Outstanding Shares
27,877,000
Free Float
12,433,000
Market Cap
$66.63 million
Optionable
Optionable
Beta
0.28

Social Links

10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:IMMX) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners